US Patent
US8058280 — Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof
Composition of Matter · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2026-01-28 · 0y expired
Vulnerability score
0/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects a class of compounds, specifically substituted thieno[2,3-d]pyrimidin-2,4-dione compounds, and their uses.
USPTO Abstract
The present invention provides a compound represented by the formula: wherein R 1 is a C 1-4 alkyl; R 2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1â²) a halogen, (2â²) a hydroxy group, (3â²) a C 1-4 alkyl and (4â²) a C 1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1â²) a halogen, (2â²) a C 1-4 alkoxy-C 1-4 alkyl, (3â²) a mono-C 1-4 alkyl-carbamoyl-C 1-4 alkyl, (4â²) a C 1-4 alkoxy and (5â²) a mono-C 1-4 alkylcarbamoyl-C 1-4 alkoxy, or the like; R 3 is a C 1-4 alkyl; R 4 is a C 1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.
Drugs covered by this patent
- Estrace (ESTRADIOL) · Pfizer
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.